News | November 01, 2021
GlaxoSmithKline posts Q2FY22 consolidated PAT at Rs. 204.24 Cr
GlaxoSmithKline Pharmaceuticals Limited has reported consolidated financial results for the period ended September 30, 2021
GlaxoSmithKline Pharmaceuticals Limited has reported consolidated financial results for the period ended September 30, 2021
Dr. Reddy's Laboratories has reported consolidated financial results for the period ended September 30, 2021
Marketing authorisation holders are advised to submit any type IB variations or groupings of type IBs and type IAs by 3rd December 2021 for a start of procedure in 2021
It provides an option to automatically perform nodule detection immediately after chest X-ray imaging
The NFI is published to promote the rational use of medicines in the country.
Two leaders in science combine complementary best-in-class technologies for biologics manufacturing customers
Generalized pustular psoriasis is characterized by episodes of widespread eruptions of painful, sterile pustules
The release of this batch will secure the supply for hospitals and cancer centres that are involved in the clinical trials managed by the company
Its unique technology, ChetoSensar gives new promise to ADCs by alleviating solubility challenges
The acquisition expands Takeda’s immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging T cells for the potential treatment of solid tumours and haematological malignancies
Subscribe To Our Newsletter & Stay Updated
